Diabetic cardiomyopathy is a type of cardiovascular damage present in patients suffering from diabetes. It is characterized by myocardial dilatation and hypertrophy as well as a decrease in the systolic and diastolic functions of the left ventricle, and its presence is independent of the coexistence of ischemic heart disease or hypertension. Existence of this condition in a diabetic patient may have several therapeutic implications including: improving glycemic control, earlier use of calcium channel blockers (CCBs), ACE inhibitors and ARBs, exercise training, lipid-lowering therapy, and antioxidant and insulin-sensitizing drugs. Increasing evidence suggests that hyperglycemia is central to the pathogenesis of diabetic cardiomyopathy, which triggers a series of maladaptive events leading to cardiomyocyte apoptosis, collagen deposition, and cardiac fibrosis.
DelveInsight’s, “Diabetic Cardiomyopathy Pipeline Insight, 2021,” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Diabetic Cardiomyopathy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Some of Diabetic cardiomyopathy Companies are:
Request for free Sample Page: https://www.delveinsight.com/sample-request/diabetic-cardiomyopathy-pipeline-insight
DelveInsight’s Diabetic cardiomyopathy report covers around 3+ products under different phases of clinical development like:
Some of Diabetic cardiomyopathy Therapies are:
Current Diabetic cardiomyopathy Treatment Scenario and Diabetic cardiomyopathy Emerging Therapies:
Table of Contents:
Introduction
Executive Summary
Diabetic Cardiomyopathy: Overview
Pipeline Therapeutics
Therapeutic Assessment
Diabetic Cardiomyopathy – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Diabetic Cardiomyopathy Collaboration Deals
Late Stage Products (Phase III)
AT-001: Applied Therapeutics
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
IMB-101897: Imbria Pharmaceuticals
Pre-clinical and Discovery Stage Products
Drug name: Company name
Inactive Products
Diabetic Cardiomyopathy Key Companies
Diabetic Cardiomyopathy Key Products
Diabetic Cardiomyopathy- Unmet Needs
Diabetic Cardiomyopathy- Market Drivers and Barriers
Diabetic Cardiomyopathy- Future Perspectives and Conclusion
Diabetic Cardiomyopathy Analyst Views
Appendix
Request for Detailed TOC: https://www.delveinsight.com/sample-request/diabetic-cardiomyopathy-pipeline-insight
About DelveInsight DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Ankit NigamEmail: Send EmailPhone: +19193216187Address:304 S. Jones Blvd #2432 City: AlbanyState: New YorkCountry: United StatesWebsite: https://www.delveinsight.com/report-store/diabetic-cardiomyopathy-pipeline-insight